Tirofiban (Aggrastat)
Jump to navigation
Jump to search
Introduction
Tradename: Aggrastat.
Indications
- adjunctive agent with angioplasty (PTCA)*
- may be useful for acute coronary syndrome
- without persistent ST segment elevation[2]
* reserved for use at the time of percutaneous coronary intervention[3]
Contraindications
- active internal bleeding
- intracranial pathology
- systolic blood pressure > 180 mm Hg
- diastolic blood pressure > 110 mm Hg
- acute pericarditis
- history of stroke
- any history of hemorrhagic stroke
- history of ischemic stroke within last 30 days
- major surgical procedure or severe trauma within the last 30 days
Adverse effects
- bleeding 17%
- pelvic pain 6%
- coronary artery dissection 5%
- bradycardia 4%
- drug adverse effects of antiplatelet agents
- drug adverse effects of glycoprotein IIb/IIIa inhibitor
- drug adverse effects of antithrombotic agent(s)
Mechanism of action
- inhibits glycoprotein IIb/IIIa receptor
More general terms
Additional terms
References
- ↑ Merk & Co. package insert
- ↑ Jump up to: 2.0 2.1 Journal Watch 22(6):47, 2002 Boersma E et al, Lancet 359:189, 2002
- ↑ Jump up to: 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022